POMDOCTOR LIMITED Announces Pricing of Initial Public Offering

Rhea-AI Summary

POMDOCTOR (NASDAQ:POM) priced its initial public offering of 5,000,004 ADSs at $4.00 per ADS, implying aggregate gross proceeds of approximately $20.0 million before underwriting discounts and expenses. Six ADSs represent one Class A ordinary share. The ADSs were approved to list on the Nasdaq Global Market and are expected to commence trading on October 8, 2025 under the ticker POM. The offering is expected to close on or about October 9, 2025 and includes a 45-day underwriter option for 750,000 ADSs.

Positive

• Gross offering proceeds approximately $20.0 million
• Listing approved on Nasdaq Global Market with ticker POM
• 6 ADSs equal one Class A ordinary share (share ratio explicit)
• Underwriters granted 750,000 ADS option exercisable within 45 days

Negative

• Gross proceeds stated before underwriting discounts and expenses
• Overallotment option equals 15% of initial ADSs, potentially increasing supply

Insights

Capital markets strategist

POMDOCTOR priced a Nasdaq IPO for $4.00 per ADS to raise about $20.0 million, signaling market access and immediate liquidity.

POMDOCTOR LIMITED will offer 5,000,004 ADSs at $4.00 each, with six ADSs equal to one Class A ordinary share, and an underwriter option for 750,000 ADSs. The ADSs are approved to list on the Nasdaq Global Market under the ticker POM and the offering is expected to close on or about October 9, 2025.

Capital flow is the immediate business mechanism: the company expects gross proceeds of about $20.0 million before fees, which increases cash on the balance sheet and supports growth or operations. This depends on successful closing, exercise (or not) of the underwriter option, and customary closing conditions; underwriting discounts and expenses will reduce net proceeds.

Key risks include execution of the closing and typical post‑IPO costs. Watch the actual closing on or about October 9, 2025, any exercise of the 45‑day greenshoe option, and subsequent SEC‑filed final prospectus disclosures for use of proceeds and dilution details.

GUANGZHOU, China, Oct. 8, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the pricing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to commence trading on October 8, 2025 under the ticker symbol "POM."

The Company expects to receive aggregate gross proceeds of approximately US$20.0 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters an option to purchase up to an additional 750,000 ADSs, exercisable within 45 days from the date of the final prospectus at the public offering price, less underwriting discounts. The Offering is expected to close on or about October 9, 2025, subject to the satisfaction of customary closing conditions.

The Offering is being conducted on a firm commitment basis. Joseph Stone Capital, LLC is acting as the underwriter for the Offering (the "Underwriter").

A registration statement on Form F-1 relating to the Offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-285771), as amended, and was declared effective by the SEC on September 30, 2025. The Offering is being made only by means of a prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from Joseph Stone Capital, LLC by email at corporatefinance@josephstonecapital.com, by standard mail at 585 Stewart Avenue, Unit L60-C, Garden City, NY 11530, or by telephone at +1 888-302-5548. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-pricing-of-initial-public-offering-302578214.html

SOURCE POMDOCTOR LIMITED

FAQ

When will POMDOCTOR (POM) begin trading on Nasdaq?

The ADSs are expected to commence trading on October 8, 2025 under the ticker POM.

How many ADSs did POMDOCTOR price in its IPO and at what price?

POMDOCTOR priced 5,000,004 ADSs at $4.00 per ADS.

What are the expected gross proceeds from POMDOCTOR's IPO (POM)?

The company expects aggregate gross proceeds of approximately $20.0 million before fees and expenses.

Does POMDOCTOR have an overallotment option in the IPO?

Yes; underwriters have an option to purchase up to 750,000 ADSs, exercisable within 45 days.

What is the ADS-to-share ratio for POMDOCTOR (POM)?

Six ADSs represent one Class A ordinary share for POMDOCTOR.

When is the expected closing date for POMDOCTOR's offering?

The offering is expected to close on or about October 9, 2025, subject to customary closing conditions.